China SXT Pharmaceuticals, Inc. — Form 20-F Summary
Reporting period: Fiscal year ended March 31, 2021, compared with fiscal years ended March 31, 2020 and March 31, 2019. The supplied request references “2020 Q4,” but the filing is an annual report, not a quarterly filing. Financial statements are prepared under U.S. GAAP and substantially reflect the operations of the company’s PRC variable interest entity, Taizhou Suxuantang.
Business context
China SXT is a British Virgin Islands holding company whose principal operations are conducted in China through subsidiaries and contractual VIE arrangements. The company researches, manufactures and sells traditional Chinese medicine pieces, including Advanced TCMP, Fine TCMP, Regular TCMP and TCM Homologous Supplements. As of March 31, 2021, the company had 15,525,094 ordinary shares outstanding and traded on Nasdaq under SXTC.
Financial performance and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $4.78 million | $5.16 million | Down 7% |
| Gross profit | $2.84 million | $2.70 million | Up 5% |
| Gross margin | 59.4% | 52.4% | Up 7.0 percentage points |
| Operating loss | $2.20 million | $1.34 million | Loss increased 64% |
| Net loss | $2.75 million | $10.29 million | Loss decreased 73% |
| Net loss margin | Approximately 57.5% | Approximately 199.3% | Improved |
| Operating cash flow | $(1.32) million | $0.93 million | Shifted to outflow |
| Investing cash flow | $(5.81) million | $(5.50) million | Higher outflow |
| Financing cash flow | $12.41 million | $3.02 million | Higher inflow |
| Cash and cash equivalents | $13.33 million | $7.29 million | Up 83% |
| Total liabilities | $18.59 million | $12.30 million | Up 51% |
| Shareholders’ equity | $15.96 million | $9.40 million | Up 70% |
Current assets were $23.23 million and current liabilities were $18.58 million at March 31, 2021, producing reported working capital of approximately $4.65 million. Amounts due to related parties were $12.15 million, non-interest-bearing and payable on demand. Bank debt was limited to approximately $43,000 in total, and no convertible notes remained outstanding at year-end.
Revenue mix and material changes
- Advanced TCMP revenue increased 12% to $1.77 million and represented approximately 37% of revenue, compared with 31% in FY2020.
- Fine TCMP revenue decreased 44% to $0.58 million, primarily due to changed requirements for certain products under the China Pharmacopoeia.
- Regular TCMP revenue decreased 36% to $1.45 million, reflecting COVID-19 effects and management’s shift away from lower-margin products.
- TCMHS revenue increased 264% to $0.97 million following the launch of four solid beverage products.
- Gross margin improved because of lower cost of revenue and a more favorable product mix, while general and administrative expenses increased 40% to $3.45 million.
- General and administrative expense growth was driven principally by increased bad-debt and inventory impairment provisions.
- Net loss improvement was primarily attributable to the absence of the $5.63 million debt-extinguishment loss recorded in FY2020 and lower convertible-note financing costs.
Cash flow, debt and unusual items
- Operating cash flow was negative despite the lower reported net loss. Cash outflows included increases in accounts receivable, staff IOUs, advances to suppliers and accounts payable movements.
- Investing outflows included an $8.85 million acquisition deposit, partly offset by $3.13 million received from the withdrawal of a Huangshan Panjie investment. The company expects to receive the remaining investment balance and interest before December 31, 2022, but does not guarantee collection.
- Financing inflows primarily consisted of $12.53 million received from related parties. The company states it expects to repay the related-party balance from cash and operating cash flow.
- The company issued shares with a reported fair value of $7.68 million to settle convertible-note principal and interest. It also issued a warrant for 250,000 post-split ordinary shares, recorded at a fair value of $509,000.
- Management stated that available cash and anticipated operating cash flow should satisfy liquidity needs for at least 12 months, while also stating that additional debt or equity financing will be needed in the near future.
Outlook, commentary and risks
Management’s strategy is to expand Advanced TCMP and TCMHS products, increase brand recognition, broaden distribution and develop additional products. No specific revenue, earnings or margin guidance was provided. Management expects revenue growth and expense reductions but acknowledges the need for additional financing and the possibility of curtailing operations if sufficient capital is unavailable.
- COVID-19 disrupted production, logistics and demand; management reported that production returned to normal levels in May 2020, but future outbreaks remain a risk.
- Two significant customers accounted for 19.37% and 15.31% of FY2021 revenue, creating customer-concentration risk. Related-party sales represented $884,990 of FY2021 revenue.
- The company depends on a VIE structure rather than direct ownership of its principal operating entity. PRC regulatory action or failure to enforce the contractual arrangements could materially impair control over operations and assets.
- Operations require PRC pharmaceutical permits and compliance with GMP and NMPA requirements. The Pharmaceutical Manufacturing Permit expires December 17, 2025; the reported GMP certification was effective through August 4, 2024.
- The company faces PRC price controls, foreign-exchange restrictions, supply-chain and raw-material risks, competition, product-liability exposure and limited insurance coverage.
- The company’s auditor is subject to PCAOB inspection according to the filing, but the filing highlights HFCA Act and potential Nasdaq delisting risks for China-based issuers.
- Management concluded that disclosure controls and internal control over financial reporting were not effective as of March 31, 2021. Reported weaknesses included insufficient U.S. GAAP-capable accounting personnel, inadequate training and insufficient segregation of duties.
- The company has never paid dividends and does not expect to pay dividends in the foreseeable future.
Most important facts for an investor to verify
- Reconcile the filing’s inconsistent references to FY2021 net loss: the audited statements report $2.75 million, while one going-concern discussion refers to $2.24 million.
- Confirm the collectability and timing of the remaining Huangshan Panjie investment balance and the overdue $1.5 million loan receivable from RH Holdings Management.
- Assess the repayment terms and source of funds for the $12.15 million related-party payable.
- Review the $8.85 million acquisition deposit, including target-company due diligence, approval status, refund rights and valuation.
- Evaluate whether negative operating cash flow, customer concentration and required future financing could create dilution or liquidity pressure.
- Monitor remediation of the disclosed material weaknesses and the effectiveness of the company’s disclosure controls.
- Review the enforceability and regulatory status of the PRC VIE arrangements, required permits, GMP compliance and exposure to evolving PRC overseas-listing rules.